Dynavax Technologies Corporation Company Profile (NASDAQ:DVAX)

About Dynavax Technologies Corporation (NASDAQ:DVAX)

Dynavax Technologies Corporation logoDynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:DVAX
  • CUSIP: 26815810
  • Web: www.dynavax.com
  • Market Cap: $1.12 billion
  • Outstanding Shares: 54,747,000
Average Prices:
  • 50 Day Moving Avg: $21.24
  • 200 Day Moving Avg: $12.36
  • 52 Week Range: $3.20 - $24.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.25
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $7.71 million
  • Price / Sales: 144.86
  • Book Value: $2.57 per share
  • Price / Book: 7.94
  • EBITDA: ($94,160,000.00)
  • Net Margins: -1,323.99%
  • Return on Equity: -92.09%
  • Return on Assets: -78.45%
  • Current Ratio: 11.93%
  • Quick Ratio: 11.93%
  • Average Volume: 2.84 million shs.
  • Beta: 1.48
  • Short Ratio: 1.94

Frequently Asked Questions for Dynavax Technologies Corporation (NASDAQ:DVAX)

What is Dynavax Technologies Corporation's stock symbol?

Dynavax Technologies Corporation trades on the NASDAQ under the ticker symbol "DVAX."

How were Dynavax Technologies Corporation's earnings last quarter?

Dynavax Technologies Corporation (NASDAQ:DVAX) released its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.41) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.50) by $0.09. The business had revenue of $0.11 million for the quarter, compared to analysts' expectations of $0.15 million. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. During the same quarter in the previous year, the firm posted ($0.75) earnings per share. View Dynavax Technologies Corporation's Earnings History.

When will Dynavax Technologies Corporation make its next earnings announcement?

Dynavax Technologies Corporation is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Dynavax Technologies Corporation.

Where is Dynavax Technologies Corporation's stock going? Where will Dynavax Technologies Corporation's stock price be in 2017?

5 analysts have issued twelve-month price targets for Dynavax Technologies Corporation's shares. Their forecasts range from $24.00 to $30.00. On average, they anticipate Dynavax Technologies Corporation's stock price to reach $27.80 in the next twelve months. View Analyst Ratings for Dynavax Technologies Corporation.

What are analysts saying about Dynavax Technologies Corporation stock?

Here are some recent quotes from research analysts about Dynavax Technologies Corporation stock:

  • 1. According to Zacks Investment Research, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. " (8/4/2017)
  • 2. Cowen and Company analysts commented, "DVAX announced that it will undergo corporate restructuring, resulting in an ~40%." (1/6/2017)

Who are some of Dynavax Technologies Corporation's key competitors?

Who are Dynavax Technologies Corporation's key executives?

Dynavax Technologies Corporation's management team includes the folowing people:

  • Arnold L. Oronsky Ph.D., Independent Chairman of the Board
  • Eddie Gray, Chief Executive Officer, Director
  • Michael S. Ostrach, Chief Financial Officer, Senior Vice President, Chief Business Officer
  • Robert L. Coffman Ph.D., Senior Vice President, Chief Scientific Officer
  • David F. Novack, Senior Vice President - Operations and Quality
  • Robert Janssen M.D., Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs
  • Laura A. Brege, Independent Director
  • Francis R. Cano Ph.D., Independent Director
  • Dennis A. Carson M.D., Independent Director
  • Daniel L. Kisner M.D., Independent Director

How do I buy Dynavax Technologies Corporation stock?

Shares of Dynavax Technologies Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dynavax Technologies Corporation's stock price today?

One share of Dynavax Technologies Corporation stock can currently be purchased for approximately $20.40.

MarketBeat Community Rating for Dynavax Technologies Corporation (NASDAQ DVAX)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  333
MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Dynavax Technologies Corporation (NASDAQ:DVAX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $27.80 (36.27% upside)
Consensus Price Target History for Dynavax Technologies Corporation (NASDAQ:DVAX)
Price Target History for Dynavax Technologies Corporation (NASDAQ:DVAX)
Analysts' Ratings History for Dynavax Technologies Corporation (NASDAQ:DVAX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017Royal Bank Of CanadaReiterated RatingOutperform -> Outperform$26.00 -> $28.00HighView Rating Details
9/15/2017Cantor FitzgeraldInitiated CoverageOverweight -> Overweight$24.00HighView Rating Details
8/10/2017Cowen and CompanyReiterated RatingOutperform$30.00HighView Rating Details
8/9/2017William BlairReiterated RatingOutperform$30.00HighView Rating Details
7/31/2017J P Morgan Chase & CoUpgradeNeutral -> Overweight$6.00 -> $27.00HighView Rating Details
9/2/2016S&P Equity ResearchBoost Price Target$11.28 -> $16.01N/AView Rating Details
(Data available from 10/22/2015 forward)


Earnings History for Dynavax Technologies Corporation (NASDAQ:DVAX)
Earnings by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)
Earnings History by Quarter for Dynavax Technologies Corporation (NASDAQ DVAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.53)N/AView Earnings Details
8/2/2017Q2 2017($0.50)($0.41)$0.15 million$0.11 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.60)($0.60)$0.75 million$0.15 millionViewN/AView Earnings Details
3/13/2017Q4 2016($0.85)($0.56)$2.90 million$7.30 millionViewN/AView Earnings Details
11/7/2016Q3($0.75)($0.90)$2.44 million$0.20 millionViewN/AView Earnings Details
8/5/2016Q2($0.68)($0.75)$1.58 million$2.65 millionViewN/AView Earnings Details
5/9/2016Q1($0.63)($0.70)$627.00 million$942.00 millionViewN/AView Earnings Details
3/8/2016Q4($0.75)($0.70)$1.15 million$0.69 millionViewN/AView Earnings Details
11/5/2015Q3($0.78)($0.82)$1.65 million$1.20 millionViewN/AView Earnings Details
8/7/2015Q2($1.00)($0.80)$3.05 million$1.55 millionViewN/AView Earnings Details
5/7/2015Q1 2015($0.95)($0.97)$1.26 million$0.63 millionViewN/AView Earnings Details
3/5/2015Q4 2014($1.06)($0.85)$2.15 million$2.28 millionViewN/AView Earnings Details
11/5/2014Q314($0.09)($0.11)$2.50 million$2.21 millionViewN/AView Earnings Details
8/7/2014Q214($0.06)($0.09)$2.26 million$3.05 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.06)($0.05)$4.22 million$3.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.07)($0.09)$1.56 million$2.80 millionViewN/AView Earnings Details
11/7/2013Q313($0.10)($0.09)$1.83 million$2.93 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.10)($0.09)$2.91 million$3.40 millionViewN/AView Earnings Details
5/6/2013Q113($0.11)($0.11)$2.40 million$2.10 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.11)$11.40 million$1.80 millionViewN/AView Earnings Details
11/1/2012Q312($0.08)($0.10)$5.00 million$2.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Dynavax Technologies Corporation (NASDAQ:DVAX)
2017 EPS Consensus Estimate: ($1.71)
2018 EPS Consensus Estimate: ($0.21)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.46)($0.46)($0.46)
Q2 20171($0.44)($0.44)($0.44)
Q3 20171($0.32)($0.32)($0.32)
Q4 20171($0.49)($0.49)($0.49)
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.11)($0.11)($0.11)
Q3 20181($0.02)($0.02)($0.02)
Q4 20181$0.09$0.09$0.09
(Data provided by Zacks Investment Research)


Dividend History for Dynavax Technologies Corporation (NASDAQ:DVAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Dynavax Technologies Corporation (NASDAQ:DVAX)
Insider Ownership Percentage: 2.90%
Institutional Ownership Percentage: 60.20%
Insider Trades by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)
Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)
Insider Trades by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/24/2017Robert JanssenVPBuy6,000$4.04$24,240.00View SEC Filing  
6/28/2016Robert JanssenVPBuy1,452$13.68$19,863.36View SEC Filing  
5/20/2016Eddie GrayCEOBuy2,750$15.57$42,817.50View SEC Filing  
5/12/2016Robert JanssenVPBuy1,000$15.12$15,120.00View SEC Filing  
8/14/2014Eddie GrayCEOBuy25,000$1.49$37,250.00View SEC Filing  
10/30/2013Peggy V PhillipsDirectorBuy93,023$1.08$100,464.84View SEC Filing  
9/14/2012Jennifer LewVPSell18,750$4.53$84,937.50View SEC Filing  
9/13/2012Robert CoffmanVPSell8,000$4.52$36,160.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Dynavax Technologies Corporation (NASDAQ:DVAX)
Latest Headlines for Dynavax Technologies Corporation (NASDAQ:DVAX)
Loading headlines, please wait.



Dynavax Technologies Corporation (DVAX) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.